STTCOMP UCM, FA Long
Uscom develops and manufactures high accuracy disruptive cardiovascular and pulmonary devices. The company’s mission is to produce non-invasive technologies that replace inaccurate, invasive technologies. The International Space Station and the Russian space program both use Uscom products. The products are IP protected and FDA, CE and CFDA regulatory approved.
Headquartered in Sydney with Global operations targeting Asia, Europe and US.
Current revenue $2m pa very close to profitability. Revenue rising 40% YOY for last 4 years Margins 60-80%
Cash $2.7m
108m shares on issue at $0.28 for $30m Market Cap.
In June they executed an agreement with China International Intellectech Corporation (CIIC) which is targeted to generate USD$48.2m (≈A$65m) in sales from China over the next five years.
The market is just starting to wake up to the magnitude of this deal and the potential of the company.
The below figure was taken from the latest presentation.
"Shareholder value, if targets achieved - $1.40 per share. ($13m sales, $6m costs, profit $7m, PE x 20, 108m shares)"
Here is the CEO and Chief Scientist Rob Phillips talking to Peter Switzer. This is before the deal was announced.
- Forums
- ASX - Short Term Trading
- Short Term Trading Week Starting: 11th July
Short Term Trading Week Starting: 11th July, page-527
-
- There are more pages in this discussion • 205 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)